Ocular Therapeutix director granted RSUs and options
Ocular Therapeutix director Leslie J. Williams received new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ocular Therapeutix director Leslie J. Williams received new equity awards. On June 10, 2026, Williams was granted 14,000 shares of common stock as restricted stock units under the company’s 2021 Stock Incentive Plan. These RSUs vest in full after one year of continued board service or just before the next annual stockholder meeting.
Williams was also granted options to buy 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036, with the same one-year vesting schedule tied to continued board service. After these grants, Williams directly holds 65,433 shares of common stock and 44,000 stock options.
Insider Trade Summary
Grant/Award: 58,000 shares
Grant/Award
2 txns
Insider
Williams Leslie J.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 44,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 14,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 44,000 contracts (Direct);
Common Stock — 65,433 shares (Direct)
Footnotes (2)
- F1. On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
- F2. Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
Key Figures
RSU grant: 14,000 shares
Option grant size: 44,000 options
Option exercise price: $8.74 per share
+3 more
6 metrics
RSU grant
14,000 shares
Restricted stock units granted June 10, 2026
Option grant size
44,000 options
Stock options granted June 10, 2026
Option exercise price
$8.74 per share
Strike price for 44,000 stock options
Option expiration
June 9, 2036
Expiration date of stock options
Common shares after grant
65,433 shares
Direct common stock holdings post-transaction
Options after grant
44,000 options
Total stock options held after grant
Key Terms
restricted stock units, 2021 Stock Incentive Plan, Stock Option (Right to Buy), vest, +1 more
5 terms
restricted stock units financial
"the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2021 Stock Incentive Plan financial
"RSUs under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc."
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vest financial
"the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price": "8.7400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Ocular Therapeutix (OCUL) report for Leslie J. Williams?
Ocular Therapeutix reported that director Leslie J. Williams received equity awards, including restricted stock units and stock options, on June 10, 2026. These awards are part of her board compensation and are subject to time-based vesting tied to continued service.
What stock options were granted to Leslie J. Williams by Ocular Therapeutix (OCUL)?
Williams was granted options to buy 44,000 shares of Ocular Therapeutix common stock at an exercise price of $8.74 per share. These options vest in full after one year of continued board service or immediately before the next annual stockholder meeting.
When do Leslie J. Williams’s new Ocular Therapeutix (OCUL) equity awards vest?
Both the restricted stock units and the stock options vest 100% on the first anniversary of the June 10, 2026 grant date. Vesting can also occur earlier, immediately prior to the next annual meeting of stockholders, if that meeting happens before the anniversary.
What are Leslie J. Williams’s Ocular Therapeutix (OCUL) holdings after these transactions?
Following the June 10, 2026 awards, Leslie J. Williams directly holds 65,433 shares of Ocular Therapeutix common stock. She also holds 44,000 stock options, each giving the right to purchase one share at an exercise price of $8.74 before June 9, 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates